相似文献
1
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
Int J Neuropsychopharmacol. 2012 Aug;15(7):1003-14. doi: 10.1017/S1461145711001738. Epub 2012 Jan 5.
2
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
Schizophr Bull. 2010 May;36(3):504-9. doi: 10.1093/schbul/sbn110. Epub 2008 Aug 22.
3
Signal detection and placebo response in schizophrenia: parallels with depression.
Psychopharmacol Bull. 2010;43(1):53-72.
4
Challenge to atypical antipsychotic drug effect on cognition.
Am J Psychiatry. 2007 Dec;164(12):1910-1; author reply 1911-2. doi: 10.1176/appi.ajp.2007.07071086.
5
Modelling and simulation of placebo effect: application to drug development in schizophrenia.
J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):377-88. doi: 10.1007/s10928-012-9296-7. Epub 2013 Jan 12.
6
Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Clin Ther. 2010 Feb;32(2):275-92. doi: 10.1016/j.clinthera.2010.02.003.
7
Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693).
J Clin Psychopharmacol. 2009 Aug;29(4):409; author reply 409-10. doi: 10.1097/JCP.0b013e3181ace863.
8
Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Arch Gen Psychiatry. 2005 Sep;62(9):961-70. doi: 10.1001/archpsyc.62.9.961.
9
Placebo reconsidered.
Can J Psychiatry. 1995 Sep;40(7):426-7. doi: 10.1177/070674379504000717.
10
[The placebo effect: general information and specificities in psychiatry (depression and schizophrenia)].
Encephale. 2012 Feb;38(1):50-7. doi: 10.1016/j.encep.2011.01.010. Epub 2011 Apr 8.
引用本文的文献
1
Placebo and nocebo phenomena in schizophrenia spectrum disorders: a narrative review on current knowledge and potential future directions.
Psychol Med. 2025 Jul 18;55:e199. doi: 10.1017/S0033291725100901.
2
Evaluation of the efficacy and safety of Yukwool-tang for major depressive disorder in women: A randomized, double blinded, placebo-controlled, parallel trial.
Medicine (Baltimore). 2024 May 24;103(21):e38208. doi: 10.1097/MD.0000000000038208.
3
The Placebo Effect in Psychosis: Why It Matters and How to Measure It.
Biol Psychiatry Glob Open Sci. 2023 Mar 5;3(4):605-613. doi: 10.1016/j.bpsgos.2023.02.008. eCollection 2023 Oct.
4
Study protocol for a randomized controlled trial with rituximab for psychotic disorder in adults (RCT-Rits).
BMC Psychiatry. 2023 Oct 23;23(1):771. doi: 10.1186/s12888-023-05250-5.
5
Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India.
Ann Indian Acad Neurol. 2022 May-Jun;25(3):433-440. doi: 10.4103/aian.aian_199_22. Epub 2022 Jun 9.
6
The Impact of Aberrant Data Variability on Drug-Placebo Separation and Drug/Placebo Response in an Acute Schizophrenia Clinical Trial.
Schizophr Bull Open. 2021 Aug 7;2(1):sgab037. doi: 10.1093/schizbullopen/sgab037. eCollection 2021 Jan.
7
Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder: A Meta-Analysis and Comparison of Meta-Regression and MetaForest.
Int J Neuropsychopharmacol. 2022 Jan 12;25(1):26-35. doi: 10.1093/ijnp/pyab054.
8
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.
Neuropsychopharmacology. 2021 Mar;46(4):844-850. doi: 10.1038/s41386-020-00911-5. Epub 2020 Nov 26.
9
Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.
Front Psychiatry. 2020 May 14;11:369. doi: 10.3389/fpsyt.2020.00369. eCollection 2020.
10
Understanding placebo and nocebo effects in the context of sport: A psychological perspective.
Eur J Sport Sci. 2020 Apr;20(3):293-301. doi: 10.1080/17461391.2020.1727021. Epub 2020 Feb 23.
本文引用的文献
1
Trial design issues and treatment effect modeling in multi-regional schizophrenia trials.
Pharm Stat. 2010 Jul-Sep;9(3):217-29. doi: 10.1002/pst.439.
2
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.
3
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
Neuropsychopharmacology. 2010 Jan;35(2):581-90. doi: 10.1038/npp.2009.164.
4
Activation of the opioidergic descending pain control system underlies placebo analgesia.
Neuron. 2009 Aug 27;63(4):533-43. doi: 10.1016/j.neuron.2009.07.014.
5
Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response.
J Physiol. 2009 Aug 1;587(Pt 15):3869-83. doi: 10.1113/jphysiol.2009.169425. Epub 2009 Jun 22.
6
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15.
7
Neurobiological mechanisms of placebo responses.
Ann N Y Acad Sci. 2009 Mar;1156:198-210. doi: 10.1111/j.1749-6632.2009.04424.x.
8
Sources of unreliability in depression ratings.
J Clin Psychopharmacol. 2009 Feb;29(1):82-5. doi: 10.1097/JCP.0b013e318192e4d7.
9
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
Schizophr Bull. 2010 May;36(3):504-9. doi: 10.1093/schbul/sbn110. Epub 2008 Aug 22.
10
New insights into the placebo and nocebo responses.
Neuron. 2008 Jul 31;59(2):195-206. doi: 10.1016/j.neuron.2008.06.030.
Zotero 插件
